An internal standard for the quantification of cilostazol
Related Products
Unlabeled Version(s)
15035Cilostazol
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Cilostazol-d4

Item No. 31790

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
6-(4-(1-(cyclohexyl-2,2,6,6-d4)-1H-tetrazol-5-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one
CAS Number
1215541-47-1
Molecular Formula
C20H23D4N5O2
Formula Weight
373.5
Purity
≥99% deuterated forms (d1-d4)
Formulation
A solid
Solubility(Learn about Variance in Solubility)
DMSO: Slightly solubleMethanol: Slightly soluble
SMILES
O=C(N1)CCC2=C1C=CC(OCCCCC3=NN=NN3C4C([2H])([2H])CCCC4([2H])[2H])=C2
InChi Code
InChI=1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)/i6D2,7D2
InChi Key
RRGUKTPIGVIEKM-KXGHAPEVSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $395

    Add
    Product Description

    Cilostazol-d4 is intended for use as an internal standard for the quantification of cilostazol (Item No. 15035) by GC- or LC-MS. Cilostazol is a phosphodiesterase 3A (PDE3A) inhibitor (IC50 = 0.2 µM for the platelet enzyme).1 It is selective for PDE3A over PDE1, -2, -4, and 5 (IC50s = >5 µM for all). Cilostazol inhibits collagen- or ADP-induced aggregation of isolated rabbit platelets (IC50s = 29 and 31 µM, respectively).2 In vivo, cilostazol (30 mg/kg) reduces thrombus formation by 84% in a mouse model of pulmonary thromboembolism. It reduces cardiac fibrosis and prevents the development of diastolic dysfunction and cardiac hypertrophy induced by a high-fat diet and angiotensin II in mice.3 Formulations containing cilostazol have been used in the treatment of the symptoms of intermittent claudication in peripheral vascular disease.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Schrör, K. The pharmacology of cilostazol. Diabetes Obes. Metab. 4 (Suppl 2), S14-S19 (2002).

    2. Koga, Y., Kihara, Y., Okada, M., et al. 2(1H)-Quinolinone derivatives as novel anti-arteriostenotic agents showing anti-thrombotic and anti-hyperplastic activities. Bioorg. Med. Chem. Lett. 8(12), 1471-1476 (1998).

    3. Reddy, S.S., Agarwal, H., and Barthwal, M.K. Cilostazol ameliorates heart failure with preserved ejection fraction and diastolic dysfunction in obese and non-obese hypertensive mice. J. Mol. Cell. Cardiol. 123, 46-57 (2018).